The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 13, 2023
Filed:
Oct. 02, 2018
Applicant:
Humanigen, Inc., Short Hills, NJ (US);
Inventors:
Cameron Durrant, Oxford, FL (US);
Dale Chappell, Nidwalden, CH;
Assignee:
HUMANIGEN, INC., Short Hills, NJ (US);
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); C07K 16/24 (2006.01); A61K 39/395 (2006.01); C07K 14/535 (2006.01); A61P 43/00 (2006.01); A61K 39/00 (2006.01); A61K 35/17 (2015.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2893 (2013.01); A61K 39/3955 (2013.01); A61P 43/00 (2018.01); C07K 14/535 (2013.01); C07K 16/243 (2013.01); C07K 16/2809 (2013.01); C07K 16/2887 (2013.01); A61K 35/17 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/626 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01);
Abstract
Methods of inhibiting or reducing the incidence or the severity of immunotherapy-related toxicity in a subject, the method comprising a step of administering a recombinant hGMCSF antagonist to the subject, wherein said administering inhibits or reduces the incidence or the severity of immunotherapy-related toxicity in said subject, are provided. An hGMCSF antagonist for use in methods of inhibiting or reducing the incidence or the severity of immunotherapy-related toxicity in a subject also are provided.